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Abstract
In research, appropriate statistical interpretation and methodology are essential to conduct
quality work. To interpret results, p-values are frequently used in isolation, but this is
insufficient as treatment effects, confidence intervals (CIs), and clinically important
thresholds should also be reported. Further, the equality, superiority, non-inferiority, and
equivalence frameworks have critical differences not well delineated in current literature. We
conducted a systematic review of studies published in high-impact orthopaedic journals and
examined a) how well studies interpreted the results of patient-reported outcome measures,
and b) whether a consistent framework was used throughout studies. We found that the
majority of studies do not report CIs around between-group differences and do not define a
clinically meaningful difference. Half of studies reporting sample size calculations had
inconsistency between framing of their research question, sample size calculation, and
conclusion. Authors should report results with clinical context and maintain framework
consistency to prevent misleading treatment recommendations.
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Summary for Lay Audience
A general understanding of important concepts such as basic statistics and methods are
needed to conduct research, however, published research may still contain misinterpreted
results. For example, authors rely on the widely used p-value statistic to measure the
difference between groups. However, p-values only tell us that two treatment differ but not
how large that difference is. The size of the difference is best communicated through
providing the treatment effect, confidence intervals (CIs), and a threshold of clinical
importance. Clinical importance indicates whether the effect of a treatment is meaningful
from a clinician’s perspective. Researchers are also interested in knowing whether their
findings are applicable to patients, which requires the use of correct study methods,
particularly the right framework (i.e. equality, superiority, non-inferiority, and equivalence).
The purpose of our study was to review studies published in top journals in the field of
orthopaedic surgery and evaluate whether studies correctly reported their results and whether
authors followed a consistent framework throughout their study. We looked at studies
published in 2017 and 2019 in five journals that compared two different treatments and
assessed patient-reported outcome measures, which are tools used to gain the patient’s
perspective. We found that the majority of studies relied on a p-value statistic, and only
approximately one in five studies reported treatment effect with CIs. We also found that
52.2% of studies switched the framework throughout their study, which led to the wrong
sample size being used and too few study participants to make treatment recommendations.
Overall, when statistics are misinterpreted and the inappropriate methodology is applied, the
study findings can lead clinicians into making misleading treatment recommendations to
patients. We encourage journal editors and authors to work on ensuring that the results of
their research are interpreted with clinical relevance and the correct framework is used. We
believe that this will improve the quality of orthopaedic literature moving forward.
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Chapter 1

1

Introduction

1.1 Introduction: Background and Rationale
Scholarly experts and journal editors assess manuscript submissions to peer-reviewed
journals in order to determine the quality of research and whether the manuscript is
suitable for publication. Despite this rigorous review process, manuscripts with
methodological and statistical issues are often accepted for publication1–3. Improper
analyses or misinterpretation of results may lead to erroneous conclusions, which can
negatively impact patient care if treatments that do not provide benefit are accepted into
practice or a treatment is discarded early due to negative findings4. The peer-review
process should identify minor and major issues with the submission, but the process itself
is inconsistent. Sprowson et al. (2013) state that in orthopaedics, hundreds of reviewers
are recruited and therefore formal training is difficult to achieve, and most reviewers
learn to review by practice5. Some journals may have statistical experts to assist with the
review process, but not all have the resources to include a reviewer with statistical
expertise on each submission. Providing clinicians with resources related to appropriate
research methodology and statistics can assist them when reviewing manuscripts and
conducting their own research.
Common mistakes authors make when analyzing or interpreting study results in
orthopaedic journals include making comparisons of p-values, missing measures of
precision and estimate of effects, and failing to differentiate between statistical
significance and clinical importance6. To determine clinical importance, patient-reported
outcome measures (PROMs) are widely used in orthopedics7, however, the interpretation
of PROMs is challenging because it is difficult to assign meaning to differences between
groups in units of a measured health outcome. PROMs are often reported using p-values,
however, the threshold p-value<0.05 is arbitrary and does not represent clinical
importance8. Rather, studies should be reporting results beyond p-values and should
include treatment effect(s) and measures of precision (i.e. confidence intervals (CIs)) to
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provide an interpretation of results that are more clinically relevant9. In addition, the
treatment effect and CIs should be interpreted in light of a clinically important threshold
to provide clinicians with context; this can be the minimal clinically important difference
(MCID), expected difference, superiority margin, or non-inferiority margin10–12. Correct
methodology and a clinically relevant interpretation of results is necessary for authors
seeking to make treatment recommendations.
Other common methodological errors of studies published in orthopedic journals involve
concepts such as the failure to follow the principles of trial design and the lack of
justification for power analysis6. An important component of trial design is the
identification of a framework that is consistent with the trial’s objective to test the
equality, superiority, non-inferiority, or equivalence between interventions13. An equality
framework is explanatory and is generally used to test the safety and feasibility of a
treatment prior to its implementation in a large scale trial14. This framework relies on pvalues to determine if a study should be pursued further, requires fewer patients, and uses
surrogate or lab-based measures to evaluate patient outcomes15,16. On the other hand, the
superiority, non-inferiority, and equivalence frameworks relies on CIs and thresholds for
clinical importance when interpreting results, making it possible to make clinical
recommendations; these a priori thresholds are, importantly, used to calculate sample
size15. As a result, these frameworks require more patients and investigate patient
important outcomes10,17. Defining a framework and using the appropriate methodology is
essential to prevent authors from overstating clinical conclusions based on underpowered
studies. In current clinical health research, the quality of reporting of these frameworks is
poor10,18.
The issues identified in the literature reflect our own anecdotal experiences with the
manuscript submission and peer review process. As part of my coursework, I took my
supervisor’s (Dr. Dianne Bryant) course “Advanced Quantitative Research Methods”;
this taught me the ways that authors may misinterpret data and how to determine the
correct study methodology based on the research question being asked. Further, my
experience conducting systematic reviews and using quality rating tools such as Grading
of Recommendations, Assessment, Development, and Evaluations (GRADE)19 and

3

Cochrane’s Risk of Bias tool (ROB)20 trained me to critically appraise study findings and
determine evidence quality. After expressing my interest in data misinterpretation and
inconsistent study methods, my supervisor presented me with a project that aimed to
evaluate both.
The past 20 years in orthopaedic research have given rise to landmark papers whose
findings led to changes in clinical practice; it is clear that the results of research are
important for the progress of medicine21,22. The quality of orthopaedic research has
improved over time, but there is a gap in the current literature on reviews that analyze the
interpretability of the results of PROMs and analyze the use of all four frameworks in
published studies. To address this gap, we sought to publish two systematic reviews that
seek to answer two questions, 1) Were studies reporting and interpreting the results of
their PROMs appropriately; and 2) Were authors following a consistent methodological
framework throughout their study?

1.2 Thesis Outline
This introduction is followed by three chapters (Chapters 2-4). Chapter 2 is a systematic
review assessing clinical studies published in five high impact orthopaedic journals to
evaluate the reporting and interpretation of the results of PROMs by determining the
proportion that, (1) only report a p-value, (2) report a treatment effect, CI, or MCID, and
(3) offer an interpretation of the results beyond interpreting a p-value. Chapter 3 is a
systematic review that evaluates the same studies from Chapter 2 to answer whether (1)
studies follow a consistent framework between their research question, sample size
calculation, and conclusion, and (2) studies should have been framed differently based on
the compared interventions. Chapter 4 comprises the general conclusion and future
directions.
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Chapter 2

2

Interpreting Patient-Reported Outcome Measures in
Orthopaedic Surgery: A Systematic Review

2.1 Introduction
The Consolidated Standards of Reporting Trials (CONSORT) Statement includes a 25item checklist recommending that studies report results beyond p-values. The statement
proposes that treatment effect(s) and measures of precision (i.e. 95% confidence intervals
(CI)) be included to facilitate the interpretation of results1. However, a 2013 review of
medical and surgical literature found less than 40% of included studies reported treatment
effects with CIs2. This suggests that authors, peer-reviewers, and journal editors may not
appreciate the extreme limitations of p-values to interpret findings2. A p-value in
isolation only describes whether the outcomes of two or more treatments differ
statistically, but does not sufficiently describe the magnitude of, or certainty around, the
estimate of the effect3. In addition, a study that reports a statistically significant
difference should carry much less influence over clinical decision-making than a study
that reports a clinically important difference. Specifically, the effects of treatment can be
statistically significant but not clinically important; or the effects of treatment can be not
statistically significant, which may mean that the treatment is ineffective, that the study
lacks precision, or that there has been a random sampling error4 (Figure 2-1).
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Figure 2-1. A, B, C, and D represent four examples of study treatment effects with
associated 95% confidence intervals (CI). Results from study A and D provide a
consistent message that clinicians should feel confident acting upon (due to narrow
CIs that fall completely to the right (A) or completely to the left (D) of a clinically
important threshold). The results from study B and C do not provide a consistent
message (due to wide CIs which include both the possibility that between-group
difference surpass a clinically important threshold and that it does not).
A treatment effect is a measure of the magnitude of the difference between groups and
may be expressed as a mean difference, odds ratio, relative risk, Cohen’s d effect size,
risk difference, median, or mean change5. Further, the associated CI provides valuable
information regarding the variability of the data and the precision of the effect. A 95%
(the conventionally used confidence level) CI represents the range of values where the
true value of a parameter lies 95% of the time and provides a degree of confidence for the
interval of the estimate3,6. Narrow CIs indicate more precise results due to a large sample
size (continuous outcome), large number of events (dichotomous outcome), or low
variability between groups7. CIs should be interpreted with respect to a threshold that
defines a clinically important difference to provide clinicians with meaningful context.
Common threshold include the minimal clinically important difference (MCID) (the
threshold representing the smallest meaningful benefit/value8), a superiority margin (a
pre-determined value used to declare that one treatment is better than another) or a noninferiority margin (a pre-determined value used to declare that one treatment is not worse
than another)10. For example, Smekal et al. randomized patients with a displaced
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midshaft clavicular fracture to receive elastic stable intramedullary nailing (ESIN) (n=30)
or non-operative treatment (n=30)9. They found statistically significant (p<0.05)
differences on the Disability of the Shoulder and Arm (DASH) scores in favour of ESIN,
and conclude that ESIN should be an alternative to non-operative treatment9. However,
they did not report the difference between groups (treatment effect), CIs, or any means to
interpret the CIs, such as a MCID, making it difficult to interpret whether this difference
is likely to be meaningful to patients or clinicians.
Patient-reported outcome measures (PROMs) are frequently used in orthopaedics to
quantify a patient’s perspective of their quality of life, function, and pain. However, the
interpretability of the results of a study reporting PROMs is challenging because it is
difficult to assign meaning to differences between groups in units of quality of life. To
date, no studies have evaluated the quality of reporting and interpretation of the results of
PROMs in orthopaedic literature. The objective of this systematic review was to assess
clinical studies from five high impact orthopaedic journals to evaluate the reporting and
interpretation of the results of PROMs by determining the proportion that, (1) only report
a p-value, (2) report a treatment effect, CI, or MCID, and (3) offer an interpretation of the
results beyond interpreting a p-value.

2.2 Methods
This systematic review was conducted in accordance with the Cochrane Handbook of
Systematic Reviews and the Preferred Reporting Items for Systematic Reviews and
Meta-Analysis (PRISMA) guidelines13,14.
Literature Search and Eligibility Criteria. We selected five orthopaedic journals with
high impact factors15 including: The American Journal of Sports Medicine (AJSM),
Journal of Bone and Joint Surgery American Edition (JBJS), Arthroscopy: The Journal of
Arthroscopic and Related Surgery, Osteoarthritis and Cartilage, and The Journal of
Arthroplasty (JOA). We systematically searched the electronic database MEDLINE to
identify eligible clinical studies published in 2017. We later updated this study to include
eligible clinical studies published in 2019.
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Study Selection. We imported all references to Covidence (www.covidence.org). Four
pairs of reviewers independently screened titles and abstracts to exclude irrelevant studies
and then reviewed full text. We included clinical studies that compared at least two
intervention groups and evaluated at least one PROM. For any disagreement, a third
reviewer was consulted. We evaluated the agreement of eligibility criteria between pairs
of reviewers for both titles and abstracts screening and full text review using a kappa coefficient (k). Agreement was interpreted as follows: almost perfect agreement (k= 0.811.00), substantial agreement (k=0.61-0.80), moderate agreement (k=0.41-0.6), and fair
agreement (k=0.21-0.40)16.
Statistical Analyses. We used proportions to report our findings and a Fisher’s chisquare test to compare results between studies published in 2017 and 2019. We used
p<0.05 to declare statistical significance and set no margin of importance for proportions.
SPSS software (version 25, IBM) was used for all statistical analyses.
Data Collection and Outcomes of Interest. Eight reviewers independently extracted
data using a standardized web-based data extraction form (Empower Health Research
Inc., http://www.empowerhealthresearch.ca/). Reviewers collected the following citation
information: study title, author, journal name, volume, page number, and study design.
Reviewers extracted the following values: p-values, estimates of the treatment effect
(mean difference, mean change, odds ratio, Cohen’s d effect size, relative risk, median,
risk difference), standard deviation or standard error or CIs, MCID, and whether a
threshold was used to interpret the importance of results (MCID, Cohen’s d effect size, or
superiority/non-inferiority margin).

2.3 Results
Our search yielded 2363 studies. The full text of 334 studies were reviewed and 228
studies were included for analysis (Figure 2-2), including: randomized control trials
(RCT) (n=126), prospective cohorts (n=35), retrospective cohorts (n=61), mixed cohorts
(n=1), and case controls (n=5). Reviewers demonstrated substantial agreement for
screening (k=0.71) and almost perfect agreement for full text review (k=0.83).
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Figure 2-2. Preferred Reporting Items for Systematic Reviews and Meta-Analyses
Flow Diagram.
Overall, 99.9% (227 of 228) of included studies presented a p-value when reporting the
results of PROMs. Of these, 31.3% (71 of 227) reported a significant p-value (<0.05) and
68.7% (156 of 227) reported a non-significant p-value (>0.05). Overall, 76.3% (174 of
228) used p-values exclusively to evaluate between group differences; 86 of 126 RCTs
reported p-values exclusively. Of the 54 (of 228) studies reporting a treatment effect,
over half (32 of 54) interpreted their results using an MCID (24 of 54), Cohen’s d effect
size (5 of 54), or a non-inferiority margin (2 of 54) (Table 2-1). Only 22.4% (51 of 228)
reported a treatment effect with associated 95% CIs and of these, three studies interpreted
CIs in the context of an MCID or non-inferiority margin (Table 2-1). Analysis of all
studies (n=228) revealed 35.5% (81 of 228) reported an MCID and 91.3% (74 of 81)
were a within-group MCID and 8.6% (7 of 81) were a between-group MCID.
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Table 2-1: Treatment Effect Reporting and Interpretation of Included Studies
(n=228)
Table 1. Treatment Effect Reporting and Interpretation of Included Studies (n=228)
Frequency, n (%)
Between-Group Treatment Effect Reported

54 of 228 (23.7)

Between-Group Treatment Effect Reported (n=54)
Mean Difference

46 of 54 (85.2)

Mean Change

5 of 54 (9.3)

Odds Ratio

2 of 54 (3.7)

Cohen’s d effect size†

1 of 54 (1.9)

Authors used a threshold to interpret the importance of results
MCID

24 of 54 (44.4)

Cohen’s d effect size††

5 of 54 (9.3)

Non-inferiority margin

2 of 54 (3.7)

Between-Group Treatment Effect with Confidence Intervals
Reported
Confidence Intervals Interpreted

51 of 228 (22.4)
3 of 51 (5.9)

MCID: Minimal Clinically Important Difference.
†: Cohen’s d effect size is a standardized effect size equal to the mean difference divided by the pooled
standard deviation.

†† These 6 studies reported the treatment effect of their patient reported outcome measure as mean
difference but interpreted findings in light of a Cohen’s d effect size, interpreting the findings based on a
small (0.2), medium (0.5), or large (0.8) treatment effect.
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Variables reported in the results were found to be not significantly different (p≥0.05)
between studies published in 2017 and 2019 with the exception of the reporting of an
MCID. We found a mean difference in proportions of 35.5% (95% CI: 20.9, 48.4,
p<0.001) indicating the true improvement in the reporting of between-group differences
using an MCID likely falls between 21% and 48%.

2.4 Discussion
Our findings reveal that the majority of comparative clinical studies published in five
high impact factor orthopaedic journals in the years 2017 and 2019 use only p-values to
report the results of PROMs. Only approximately one in five of studies reported
treatment effects with 95% CIs and slightly more than half interpreted their findings in
light of a clinically important threshold. The reporting of MCIDs was low and the
majority were within-group MCIDs, which is inappropriate for a between-group
comparison. Since evidence-based practice requires clinicians to remain up-to-date with
scientific literature, it is important that we move away from the use of arbitrary p-value
thresholds and towards reporting values that provide clinically relevant information3,17.
Conclusions in clinical studies are frequently based on a p-value in isolation, using the
threshold of 0.05 to determine whether one treatment is more effective than another18.
However, the significance level of p<0.05 is arbitrary and does not represent clinical
importance18. The p-value is influenced by sampling error, sample size, and variability:
the smaller a sample, the less likely you are to achieve statistical significance that is
reproducible19. The more variable a population, the less likely you are to achieve
statistical significance even when treatments truly offer different outcomes to patients,
unless the sample is quite large19. Conversely, the larger and more homogenous a sample,
the more likely you are to achieve reproducible statistical significance19 (Figure 2-1).
Given the highly influential nature of the study sample in achieving statistical
significance, an assessment of the likelihood of random sampling error, the precision of
the results, and readiness for uptake into practice should be a requirement of all studies
evaluating the effects of two or more interventions.
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Many of the evaluated studies reported a non-significant p-value. In most cases, these
results were misinterpreted as “no difference between treatments”. However, a p≥0.05
indicates that the null hypothesis is consistent with observed results, but it does not prove
that there is no difference between treatments20. There are many reasons for a p≥0.05,
including lack of power, imprecise or invalid measurement, poor study design (type two
error), and erroneous statistical analyses21. Because these reasons are rarely given
appropriate consideration, it is likely that potentially beneficial treatments have been
discarded based on non-statistically significant findings22,23.
Abdullah et al. conducted a systematic review of orthopaedic literature from 2012 to
2013 and found a number of RCTs (21.5%) concluded “no difference between study
groups” but were underpowered to do so23. This problem is not specific to orthopaedics.
In an analysis of five journals of various disciplines, Amrhein et al. report that 51% of
published articles incorrectly interpreted statistically non-significant results as having “no
effect”24. The authors call for the abandonment of p-values and have collected over 800
signatories from scientists in over 50 countries24.
Conversely, Bhandari et al. surveyed orthopaedic clinicians and found that when p-values
were statistically significant, clinicians perceived the study results to be more
important25. However, considering that there are at least three possible explanations for
statistically significant p-values (i.e. there is a difference in outcomes, there is a random
sampling error, or there is insufficient power to be certain) and at least three possible
explanations for results that are not statistically significant (i.e. there is no difference in
outcomes, there is a random sampling error, or there is insufficient power to be certain), it
is essential that we report results that communicate the magnitude of the treatment effect,
precision of results, and ultimately, clinical importance3,26,27.
We assessed the proportion of studies that reported results using more than just a p-value
and found that only 22.4% of studies reported the magnitude of treatment effects and
associated 95% CIs. Similarly, Vavken et al. conducted a systematic review evaluating
orthopaedic journals from 2000 to 2006 and found only 22% reported CIs28. Despite over
a decade of research, disappointingly, our reporting methods remain unchanged. When

15

comparing reporting methods to other surgical specialties, a 2015 systematic review by
Karadaghy et al. of otolaryngology literature found that 54% of studies reported a
treatment effect but only 27% reported associated CIs and even fewer (8%) interpreted
the CIs for the reader29. In our review, 57.4% of the studies that reported a treatment
effect interpreted their results with respect to a threshold (MCID, Cohen’s d effect size,
or non-inferiority margin), but only three studies interpreted findings using CIs. As
researchers, we must remember that the effect size represents the average effect for that
specific sample only; that there is a distribution of possible effect sizes where the true
effect size is most likely found within one standard deviation of this average value and
that the 95% CI describes possible values that are two standard deviations on either side
of the average. Researchers should evaluate both the upper and lower bounds of the CI
with respect to a clinically important threshold to ensure that the certainty around results
is clearly articulated30. For example, readers should consider if the study, 1) has ruled out
the probability of a clinically important difference (the study is not statistically different
and the clinically important threshold falls outside of the study CIs), 2) found a high
probability that differences are clinically important (the study is statistically significant
and the threshold falls outside (is smaller than) of the study CIs), or 3) is underpowered
to make definitive conclusions (the threshold falls within the study CIs). This will allow
clinicians to make more informed, accurate and robust decisions regarding patient care.
We found that only 35.5% of studies mentioned an MCID which is a small proportion for
a value that is essential to relay clinical importance when reporting the results of a
PROM. Copay et al. evaluated MCID reporting trends in orthopaedic journals from 2014
to 2016, and found that only 129 of 1709 articles used or referenced an MCID, where the
majority (86.1%-90.4%) used previously published MCIDs31,32. A challenge with using
an MCID to interpret study results is that the majority of MCIDs are determined using a
within-group study design; here, participants are asked to comment on whether they have
experienced small, meaningful change following an intervention and the average change
between a pre- to post- intervention score, in patients who claim to have experienced a
small but important change, is proclaimed the MCID. In terms of similarities between
within-group versus between-group studies, a pre- to post- intervention study (withingroup) might be considered similar to an unblinded no treatment versus active treatment
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comparator, in terms of measuring similar amounts of change33. Unfortunately, measured
change between two active comparators or an active comparator versus a blinded placebo
will be much smaller since the control group in both scenarios will also experience and
report change34. A 1993 study by Goldsmith et al. reported that, on average, the value of
the between-group MCID was 20-40% of the within-group MCID35 (Figure 2-3). For
example, Warby et al. randomized patients with multidirectional instability (MDI) of the
shoulder to the Watson MDI (n=18) or Rockwood (n=23) program11. Groups were
compared using the Melbourne Instability Shoulder Score (MISS) at 24 months. The
authors reported a mean between-groups difference of 15.4 MISS points (95%CI 5.9 to
24.8) but did not interpret the results for the readers. Specifically, since the 95% CIs
excluded a between-group MCID of 2.0 (approximately 40% of the within-group MCID
of 5.0), the authors could have concluded with certainty that patients who undergo the
Watson program will experience superior results to those who undergo a Rockwood
program. Assuming no selection bias, exclusion of the between-group MCID from the
95%CI means that the findings are precise.

Figure 2-3. Study A is statistically significant and is clinically important according
to the between-group minimal clinically important difference (MCID) (conclusive)
but is not clinically important according to a within-group MCID (conclusive). The
clinical interpretation is conclusive but opposite depending which MCID is
used. The results of study B are not statistically different and not clinically
important based on a within-group MCID (conclusive) but there is still a possibility
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that the difference in outcome between treatments is clinically important if using a
between-group MCID (inconclusive), since the upper boundary of the 95%
confidence interval includes the between-group threshold.
Being able to detect a smaller difference between treatments requires a larger sample size
(i.e. greater power). The denominator of the equation used to estimate sample size is
defined by the value of the expected difference between the two treatment groups
(squared). Given that the most common value that researchers use to represent the
expected difference is the within-group MCID, it is no wonder why the majority of
orthopaedic trials are underpowered. It is simply unreasonable to expect that the
difference between two active treatment groups would be as large as the difference from
pre- to post- intervention. This also means that study results interpreted using a withingroup MCID, where the expected between-groups differences are much larger than is
reasonable, may have falsely concluded that the outcomes were definitively not different
between the two groups (E.g. Study A in Figure 2-3). For example, Kvalvaag et al.
randomized patients with subacromial shoulder pain to receive supervised exercises
with radial extracorporeal shock wave therapy (rESWT) (n=69) or sham rESWT
(n=74)12. They reported a between-group difference of 0.7 (95%CI -6.9 to 8.3) on the
Shoulder Pain and Disability Index (SPADI) at 24 months12. Given that an
important between-group MCID likely falls around 4 points (40% of the 10 point withingroup MCID), if they had set a superiority margin of 2 points (given that an intervention
can still be useful even if not all patients will experience an important change), they
would be unable to definitively conclude that rESWT is not more effective than sham
because the CIs still include 2 points. If, on the other hand, the authors had used the
within-group MCID of 10 points (as is commonly done in error) they would have
erroneously concluded that we can be certain that rESWT is not better than sham.
To improve the quality of reporting in the field of orthopaedics, instructions to authors
may need to be improved and the vetting process be more comprehensive. Specifically,
we found there was inconsistency between the instructions for authors of journals
included in this review with respect to whether the reporting of treatment effects, CIs, and
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MCID were required. Further, limited availability of statistical support in some
orthopaedic groups may help explain our findings.
Our study is not without limitations. We evaluated high impact orthopaedic journals
based on the annual Journal Citation Report which is the ratio between citations and
recent citable items published which does not necessarily reflect quality36. Further, we
only evaluated studies in five journals and thus were also unable to capture the complete
breadth of the orthopaedic literature. The generalizability of our findings to other fields is
limited since the issues of significance in clinical trials are not the same as in basic
sciences, where consistency of statistically significant results between different samples
is emphasized (i.e. clinical importance is not relevant).

2.5 Conclusion
The majority of interventional studies reporting PROMs do not report CIs around
between-group differences in outcome and do not define a clinically meaningful
difference. A p-value, which cannot effectively communicate the clinical meaning of the
results, is insufficient and may be misleading. Reporting requirements should be
expanded to require authors to define and provide a rationale for between-group clinically
important difference thresholds and the study findings should be communicated by
comparing the CIs to these thresholds.
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Chapter 3

3

Inconsistencies in Methodological Framework
Throughout Published Studies in Top Orthopaedic
Journals: A Systematic Review

3.1 Introduction
The Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT)
Statement recommends that authors provide both the type and framework of the trial in
the study protocol1. The framework of a study refers to its overall objective to test the
equality, superiority, non-inferiority, or equivalence of one intervention against another1.
Depending on the framework selected, there are important differences in design, analysis,
sample size estimation, and interpretation2.
An equality framework uses a two-sided statistical test to determine the probability that
the observed differences in outcomes between a treatment and a control group are due to
chance3. This is called a null hypothesis testing framework3,4. Although we can, and
should, produce confidence intervals (CIs) around the estimate of the treatment effect
(i.e., the difference between groups), the CIs are not used to indicate anything more than
the precision of the estimate. Generally speaking, if the lower and the upper boundary of
the CI fall on opposite sides of no between-group difference (mean difference (MD) or
risk difference (RD) = 0, or relative risk (RR) or odds ratio (OR) = 1), then the statistical
test will produce a probability value greater than 5% (p>0.05) or not statistically
different4. Under this framework, studies with non-statistically significant results with
very imprecise CIs reach the same conclusion as studies with precise CIs, that the
observed difference between groups is not greater than that which might occur by chance.
The same is true of studies that reaches statistical significance; CIs could be imprecise,
range from a very small effect to a very large effect in favour of the new treatment, or
could be precise and include a smaller range of plausible effect sizes5.
Given that interpretation of the range of plausible effect sizes is not part of the equality
framework, it is appropriate for feasibility or proof of concept studies that seek to
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demonstrate that the intervention can affect change, or efficacy studies that use surrogate
outcomes (i.e., proxy measures of patient important outcomes), where the intention is to
demonstrate that change in the surrogate is possible and provide evidence to support a
more pragmatic next study (or not). The recommendation should not include making
changes to clinical care.
Conversely, a superiority framework uses a one-sided statistical test to declare whether
one treatment is better than another and makes reference to a pre-determined superiority
margin to make this declaration3,6. Studies that should use a superiority framework
generally involve introducing a new intervention to replace an existing intervention.
Here, less may be understood about the adverse event profile for the new intervention and
there may be costs associated with bringing the intervention into routine practice. As
such, clinicians should insist on certainty around these conclusions before adopting the
new treatment into practice.
A superiority framework is also appropriate when we are adding resources to an existing
intervention (e.g. providing the intervention more frequently or for a longer duration,
requiring additional equipment or time to perform a procedure, etc.). The value assigned
as the superiority margin is informed by the cost of the new intervention relative to old,
including any costs associated with retraining the clinician, replacement or retooling of
equipment, and the ability of the existing intervention to achieve desired rates and
standards of outcomes. For studies that include a patient-reported outcome measure
(PROM), the demonstrated minimally clinically important difference (MCID) for that
outcome may also factor into decisions around the magnitude of the superiority margin7.
Under a superiority framework, the superiority of one intervention over another is
declared if the CIs rule out the possibility that the true between-group difference is
unimportant.
Next, a non-inferiority framework uses a one-sided test to declare whether a treatment is
“no worse” than its control3. This framework involves defining a non-inferiority margin,
which is the maximum difference between treatments that one is willing to accept before
declaring one of the treatments inferior to the other (i.e., causing unacceptably worse
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outcomes for its recipients)8. A non-inferiority framework is appropriate for studies
evaluating whether an existing intervention, or parts of that intervention, can be removed
such that any negative affect on outcomes is within acceptable limits. The reason for
removing an intervention is likely wrapped up in reducing resource use or adding
efficiencies around existing protocols. Therefore, the value that defines the noninferiority margin is informed by the likelihood and severity of worse outcomes, and the
cost to the individual and the health care system associated with suffering a worse
outcome.
Finally, an equivalence framework seeks to assess whether two interventions are
interchangeable, offering equivalent outcomes3. This framework requires defining both a
superiority and non-inferiority margin. To be justified in declaring that two interventions
are equivalent, the CIs around the between-group difference would be completely
contained with both margins3.
Systematic reviews of medical literature evaluating the reporting and interpretation of
superiority, non-inferiority, and equivalence trials have identified deficiencies in design
and inconsistencies in methodology9,10. To address this issue, an extension of the
Consolidated Standards of Reporting Trials (CONSORT) recommendations was
developed to outline the differences between frameworks and improve the reporting of
non-inferiority and equivalence trials11. With numerous studies trying to demonstrate
superiority, non-inferiority, and equivalence of various orthopaedic interventions and
make clinical recommendations, an investigation into the reporting and interpretation of
these frameworks is warranted. Thus, the objective of this systematic review was to
assess studies published in five of the top orthopaedic journals and evaluate the
proportion of studies that (1) demonstrated consistency between the framing of their
research question, sample size calculation, and conclusion, and (2) should have framed
their research question differently based on the compared interventions.
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3.2 Methods
This systematic review was conducted in accordance with the Cochrane Handbook of
Systematic Reviews and the Preferred Reporting Items for Systematic Reviews and
Meta-Analysis (PRISMA) guidelines12,13.
Literature Search and Eligibility Criteria. We selected five orthopaedic journals with
high impact factors14, including: The American Journal of Sports Medicine (AJSM),
Journal of Bone and Joint Surgery American Edition (JBJS), Arthroscopy: The Journal of
Arthroscopic and Related Surgery, Osteoarthritis and Cartilage, and The Journal of
Arthroplasty (JOA). We systematically searched the electronic database MEDLINE to
identify eligible clinical studies published in 2017. We later updated this study to include
eligible clinical studies published in 2019.
Study Selection. We imported all references to Covidence (www.covidence.org). Four
pairs of reviewers independently screened titles and abstracts in stage one to exclude
irrelevant studies and reviewed full-text studies in stage two. We included clinical studies
published in 2017 and 2019 that compared at least two interventions and evaluated at
least one PROM. The reviewers discussed any disagreements and consulted a third
reviewer when necessary until consensus was reached. We evaluated the agreement of
study eligibility between pairs of reviewers for both titles and abstracts screening and full
text review using a kappa co-efficient (k). Agreement was interpreted as follows: almost
perfect agreement (k= 0.81-1.00), substantial agreement (k=0.61-0.80), moderate
agreement (k=0.41-0.6), and fair agreement (k=0.21-0.40)15.
Statistical Analyses. We used frequencies and percentages to report all categorical
variables. SPSS software (version 25, IBM) was used for all statistical analyses.
Data Collection and Outcomes of Interest. Four reviewer pairs independently extracted
data using a standardized web-based data extraction form (Empower Health Research
Inc., http://www.empowerhealthresearch.ca/). Reviewers collected the following citation
information: study title, author, journal name, volume, page number, study design, and
sample size. For each study, reviewers assessed the framework of the research question,
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sample size calculation, and conclusion. Each section was classified as either: equality,
superiority, non-inferiority, or equivalence. Justification for each classification was
noted. Finally, reviewers assessed studies that were framed as equality and determined
whether they should have used a different framework based on the interventions being
compared. Information regarding how studies were reframed is detailed in Appendix A.

3.3 Results

Figure 3-1. Preferred Reporting Items in Systematic Reviews and Meta-Analyses
Flow Diagram.
Our search yielded 2363 studies (Figure 3-1). The full texts of 335 studies were reviewed,
and 228 studies were included for analysis (Table 3-1). Agreement at the titles and
abstracts stage was substantial (k=0.71) and at the full text screening stage was almost
perfect (k=0.83).
Table 3-1. Type of Included Study (n=228)
Type of Study
Randomized Control Trial

Frequency, n (%)
126 (55.3)
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Prospective Cohort

35 (15.4)

Retrospective Cohort

61 (26.8)

Mixed Cohort

1 (0.4)

Case Control

5 (2.2)

Note: A mixed cohort is when one group has been
followed prospectively and compared to a group
collected retrospectively.

Of studies that reported a sample size calculation (60.5%, n=138), 52.2% (n=72)
demonstrated inconsistency between the framing of the research question, sample size
calculation, and conclusion. Of the 137 studies that reported an equality sample size
calculation, only 56.2% (n=77) were consistent with this approach in framing their
concluding statements; the remaining 43.8% (n=60) studies incorrectly concluded
superiority (n=49), non-inferiority (n=3), and equivalence (n=8).
Of studies that did not report a sample size calculation (39.5%, n=90), 42.2% (n=38)
were inconsistent between the framing of the research question and the conclusion.
Overall, 81.6% (n=186) of studies framed their research question as equality (Table 3-2).
Based on the interventions being compared, we determine that 129 studies should have
been framed as superiority, 52 as equivalence, and three as non-inferiority. Only two
studies correctly framed their research question as equality.
Table 3-2. Inconsistency within published studies regarding the alignment of the
research question, sample size calculation, and conclusion.
Research question (n=228)

Sample size calculation*

Conclusion (n=228)

(n=138)
Frequency, n
Equality
Superiority

Frequency, n

Frequency, n

186

137

128

39

0

79

30

Non-Inferiority

2

1

8

Equivalence

1

0

13

*Sample size calculation was not provided in 90 studies.

3.4 Discussion
We found that approximately half (52.2%) of the studies published in five high impact
orthopaedic journals demonstrated inconsistency between the framing of their research
question, sample size calculation, and conclusion. The majority (81.6%) of studies
framed their research question as equality instead of superiority, non-inferiority, or
equivalence, based on the interventions that were being compared. Of the studies that
reported a sample size calculation, nearly all used an equality calculation despite almost
half concluding that one intervention was superior, non-inferior, or equivalent to another.
This pattern of inconsistency is problematic, as authors may be misinterpreting research
findings and making unsubstantiated clinical recommendations based on statistical
results.
The decision as to the appropriateness of each framework can be informed by the location
of the study on the continuum of trial designs (Figure 3-2). The Pragmatic Explanatory
Continuum Indicator Summary (PRECIS) tool states that explanatory trials aim to
evaluate efficacy and safety in a highly controlled setting, whereas pragmatic trials aim to
test effectiveness and apply findings to clinical practice16. Pilot studies are a type of
explanatory trial used during the planning phase for large, expensive, pragmatic trials.
The appropriate framework for pilot studies is equality, since they aim to assess the
feasibility of the protocol, evaluate eligibility criteria, and examine safety17. In our study,
only two articles were appropriately framed as equality since they intended only to
evaluate efficacy using lab-based or surrogate outcomes17. Researchers who intend to
make clinical recommendations based on their findings should be conducting a pragmatic
study and use a superiority, non-inferiority, or equivalence framework18.
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Figure 3-2. The explanatory-pragmatic continuum of trial design.
It could be argued that changing the framework as a study progresses is a form of
outcome reporting bias, a bias that arises when the dissemination of research findings are
influenced by the nature and direction of results19. Greene et al. evaluated clinical studies
from 1992 to 1996 and found that 67% declared equivalence following a failed
superiority test20. Paesmans et al. found 11 out of 23 non-inferiority oncology studies did
not communicate their initial trial design and conclusion using the same framework10.
Finally, Shafiq and Mahlotra argue that failed non-inferiority trials claiming superiority
may be engaging in research misconduct or statistical trickery as no pre-specified
superiority margin was identified21.
As researchers, we are trying to estimate a parameter. For studies evaluating the effect of
an intervention, the parameter we are trying to estimate is the size of the difference in
treatment effect between two or more groups. A CI represents a range of values so
defined that there is a specified probability that the value of a parameter lies within it
(e.g., 99%, 95%, 80%, etc.)22. A 95% CI is an estimate of plausible values for the
population parameter23. As researchers, we infer that the results observed in our sample
apply to the population, but intuitively we know that the smaller the sample, the less
likely it is to represent the population (i.e., random sampling error or sampling bias)24.
This is why it is so important that researchers responsibly recognize the range of effect
sizes that remains plausible for the population, and this requires more than the reliance on
the p-value.
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Our study shows that there is still some uncertainty about how to frame a research study
and interpret the results correctly. For example, 33% of the studies in our review
concluded that one treatment was superior to the other. However, no studies used a
superiority margin in their sample size calculation or interpreted their CIs against a
superiority threshold. Only one study consistently and properly used a non-inferiority
framework. To declare superiority or non-inferiority, authors must stipulate a margin or
threshold that delineates the magnitude of the between-groups difference required to
declare superiority, use this margin when calculating sample size, and relate the findings
to the margin when interpreting the results (Table 3-3, Figure 3-3).
Table 3-3. Characteristics of the four methodological frameworks.
Framework

Research Question/Aim

Calculation to

Concluding Statement

Key Elements

No margin

Estimate Sample Size*
Equality

“The aim of our study

Only includes an

“Treatment A produced

was to statistically

expected difference

outcomes that are not

compare… “

Superiority

statistically different
Denominator: δ2

from Treatment B.”

“The aim of our study

Includes an expected

“Treatment A is better

Superiority

was to determine if

difference and

than Treatment B.”

margin must be

treatment A offers better

superiority margin

determined a

outcomes than treatment

priori

B…”

Denominator: (δ - M)2

Non-

“The aim of our study

Includes an expected

“Treatment A is no

Non-inferiority

Inferiority

was to determine if

difference and non-

worse than Treatment

margin must be

treatment A is no worse

inferiority margin

B.”

determined a

than treatment B…”

priori
Denominator: (δ - M)2

Equivalence

“The aim of our study

Includes an expected

“Treatment A is

Both superiority

was to determine if

difference, non-

interchangeable with,

and non-

treatment A is equivalent

inferiority margin and

comparable to, or equal

inferiority margin

to treatment B…”

superiority margin

to Treatment B.”

must be
determined a

Denominator: (M -|δ|)2

priori
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*The numerator in all sample size calculations remains the same: n/group=2(Z+ Zβ)2σ2 for outcomes that use a
continuous scale and (Z+ Zβ)2((po(1-po)) + (p1(1-p1))) for outcomes that are dichotomous. Note that Z is Zα/2 is 1.96
for a two-sided test where the Type 1 error rate is 5% (equality and equivalence) and Z is Z α/2 is 1.64 for a one-sided
test where the Type 1 error rate is 5% (superiority and non-inferiority). Note that for dichotomous outcomes, the
sample size calculation is different from continuous but similarly, only the denominator changes across frameworks.

Figure 3-3. Forest plots labelled 1, 2, 3 and 4 represents the average between-group
difference (diamond shape) with its associated 95% confidence interval (CI). In plot
1, the studies use the equality framework where the results of two separate studies
show the relationship between the CIs, no difference (0), and achieving statistical
significance. In plot 2, the studies use a superiority framework where A and C
represent definitive results, whereas the results of study B cannot offer the same
level of certainty. In plot 3, the studies are using a non-inferiority framework where
A and C represent definitive results, whereas the results of study B are inconclusive.
In plot 4, the study can conclude that the two treatments offer identical outcomes
and can be used interchangeably. If the CIs around the between-group difference
cross one or both margins, the study is inconclusive.
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The placement of the non-inferiority margin will depend on the seriousness of
experiencing worse outcomes than offered by usual care. For example, if switching to the
treatment will result in a greater number of life-threatening or irreversible outcomes, we
are unlikely to accept a large non-inferiority margin and the sample size requirements are
likely to be large even if there are substantial savings to the institution or health system.
On the hand, a more liberal non-inferiority margin may be acceptable if changing
treatment will mean an increase in the number of patients with minor adverse events,
inconveniences, or reversible, rare harmful events, especially if there are substantial
savings to the institution or health system8. The degree of subjectivity and controversy
attached to the specification of the margin has the potential to impact the uptake of
findings. Wangge et al. found wide variations in non-inferiority margins for studies
evaluating novel oral anti-coagulants after orthopaedic surgery, which led to inconsistent
conclusions about the efficacy of the novel drug25. Therefore, a transparent description of
how the clinicians arrived at the superiority or non-inferiority margin will provide readers
with the context against which recommendations from the research team stem26.
Green et al. evaluated clinical studies in a range of medical journals finding that only
23% of equivalence studies reported a pre-set margin27. In our study, we found 13 studies
that concluded that two treatments were “interchangeable”, “similar”, “not different”, or
“equivalent”. These studies interpreted a statistically non-significant result (p≥0.05) as
evidence that there was no difference between treatments. This interpretation is incorrect,
as a non-significant p-value only reveals that the null hypothesis (no difference between
groups) is consistent with the observed results, but not that the null hypothesis is true28.
Remember, we have only sampled the population and random sampling error is possible;
to be able to confidently declare equivalence or comparability between treatments
requires a definition of each margin, with justification, and a large sample size.
Reito et al. reviewed studies published in seven orthopaedic journals between 2016 and
2017, and found that the proportion of studies adequately powered to detect a clinically
important difference ranged from 0% to 53% across different subspecialties29. Of the
60.5% of studies in our review that reported a sample size calculation, nearly every study
used an equality calculation despite 43.8% claiming that one intervention was either
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superior, non-inferior, or equivalent to another. A superiority, non-inferiority, and
equivalence framework require a larger sample size than an equality framework because
the margin sets restraints on the width of the CI30. Thus, the closer the defined margin is
to the expected difference between groups, the larger the sample size requirements. We
have provided two tables that illustrate sample size requirements for equality, superiority,
and non-inferiority for varying values of the expected difference and the margins (Table
3-4, Table 3-5).
From these tables, one can see that the sample size requirements increase as the distance
becomes smaller between the margin and expected between-group difference. We have
also included the sample size requirements when no margin is instilled, where the CI just
has to remain greater than 0 (if using MD or RD) or 1 (if using RR or OR) to achieve
superiority. We have also identified values of effect size that represent within- and
between-group MCIDs, which are commonly, but incorrectly, used to inform sample size
estimates.
Specifically, the majority of MCIDs are determined using a within-group (pre- to postdesign) where the MCID is the value of the average pre-to-post change in participants
who claimed to have changed by a small but important amount following an intervention.
However, the amount of change experienced within a group, whose members are aware
that an intervention has been applied, will be larger than the difference that can be
expected between two groups who have received an active control31. This is especially
true when participants are blind to treatment group, because both groups are expected to
demonstrate change. Thus, a within-groups MCID, which is approximately equal to an
effect size of 0.5 standard deviation units32, may be an unreasonably optimistic value to
inform the expected difference in a sample size estimation.
Using an overly estimate of the expected difference between groups means that the study
will be underpowered to make precise estimates of the effect of the treatment compared
to control. It also increases the risk of a random sampling error, which means that by
chance, the sample is not representative of the population33. The chance that studies
obtain a representative sample increases with a larger sample size and multiple centres34.
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As a result, the larger sample required for a superiority, non-inferiority, or equivalence
framework improves the applicability of findings, which is ultimately the goal of
clinicians seeking to apply research findings to clinical decision-making.
Table 3-4. Sample size estimates for a superiority study (n per group).
Superiority

Delta (δ)

Margin (M)
0.55

0.50

0.45

0.40

0.35

0.30

0.25

0.20

0.15

None*

52

63

77

98

128

174

251

392

697

0

41

49

61

77

100

137

197

308

547

0.05

49

61

77

100

137

197

308

547

1230

0.10

61

77

100

137

197

308

547

1230

4920

0.15

77

100

137

197

308

547

1230

4920

0.20

100

137

197

308

547

1230

4920

0.25

137

197

308

547

1230

4920

0.30

197

308

547

1230

4920

0.35

308

547

1230

4920

0.40

547

1230

4920

0.45

1230

4920

Unless otherwise noted, sample size calculations include a one-sided alpha of 5% (Z α/2=1.64), a beta of
20% (β=0.84), and a standard deviation of 1.0.
*This represents an equality framework, where the statistical test is two-sided (Zα/2 = 1.96).
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Table 3-5. Sample size estimates for a non-inferiority study (n per group).
Non-inferiority

Delta (δ)

Margin (M)
-0.18

-0.15

-0.10

-0.05

0.0

None*

484

697

1568

6272

NA

-0.19

123008

7688

1519

628

341

-0.20

30752

4920

1230

547

308

-0.25

2510

1230

547

308

197

-0.30

854

547

308

197

137

-0.35

426

308

197

137

100

-0.40

254

197

137

100

77

-0.45

169

137

100

77

61

-0.50

120

100

77

61

49

Unless otherwise noted, sample size calculations include a one-sided alpha of 5% (Z α/2=1.64), a beta of
20% (β=0.84), and a standard deviation of 1.0.
*This represents an equality framework, where the statistical test is two-sided (Zα/2 = 1.96).
NA: Not applicable.

Our study is not without limitations. We evaluated high impact orthopaedic journals
based on the annual Journal Citation Report, which is the ratio between citations and
recent citable items published which may not always reflect quality35. Since we only
evaluated five journals, we were also unable to capture the complete breadth of
orthopaedic literature. When discussing explanatory trials, we have oversimplified the
definition because our focus was on clinical applicability and treatment
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recommendations. Further, it is likely that a large proportion of orthopaedic equality
studies using surrogate or lab-based outcomes (i.e. basic science or biomechanical
studies) are appropriately framing their research, but since our inclusion criteria evaluated
only studies with a PROM, this number is low in our review. Lastly, because we focused
on PROMs, we did not discuss this topic as it relates to dichotomous outcomes such as
failure rates, although the majority of considerations are identical.

3.5 Conclusion
In conclusion, we found that the majority of published studies in top orthopaedic journals
made conclusions based only on statistical findings and that recommendations for uptake
into practice suggest an unjustified level of certainty, given the range of plausible
treatment effects if CIs were used in place of p-values to interpret the study results.
Researchers should state and justify their methodological framework (i.e., equality,
superiority, non-inferiority, or equivalence) and choice of margin(s) in their protocol as it
has implications for sample size and the applicability of conclusions. Editors should
mandate the reporting and justification of a trial’s framework and evaluate the
consistency between the stated research question(s), sample size estimate, design
(efficacy versus pragmatic), outcomes (surrogate versus patient important), interpretation
of findings (p-values alone versus CIs), and whether recommendations to change practice
are appropriate. This level of accountability will improve the quality of clinical trials in
orthopaedics and the validity of their conclusions.
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Chapter 4

4

General Conclusion and Future Directions

4.1 General Conclusion
Understanding important statistical and methodological concepts is essential when
conducting clinical research and making informed treatment recommendations. To date,
no studies have evaluated the reporting quality of patient-reported outcome measures
(PROMs) or the use of all four methodological frameworks (equality, superiority, noninferiority, and equivalence) in orthopaedic literature. In our first study, we found that
most published studies rely solely on p-values to draw conclusions about between-groups
differences and few (approximately one in five) report treatment effects with confidence
intervals (CIs). In our second study, we found that half of the studies that reported a
sample size calculation had inconsistency between the framing of their research question,
sample size calculation, and conclusion. Our findings are problematic because p-values
do not provide information on the magnitude or clinical relevance of the difference
between treatment groups and inconsistencies in framework methodologies can lead to
inaccurate sample size calculations and misinterpreted results.
Reporting results using treatment effects with CIs and applying the appropriate
framework are essential concepts that must be considered together. P-values are often
misinterpreted; for example, authors may interpret a significant p-value as evidence for
superiority of a treatment or a non-significant p-value as evidence for no difference
between treatments. However, a p-value only indicates if a difference between groups
exists and is used as part of an equality framework to assess whether a meaningful
change is likely to occur and make a decision on whether the study may move forward to
a larger trial to determine its clinical effectiveness. A p-value, therefore, is insufficient
evidence to declare superiority, non-inferiority, or equivalence between groups. To
correctly declare superiority, equivalence, or non-inferiority, authors must report and
interpret treatment effects, CIs, and clinically important thresholds. Further, the
interpretation of treatment effects and CIs should align with the appropriate framework
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because clinically important thresholds will differ depending on the framework used and
the research question being asked. Additionally, since the precision of CIs depends, in
part, on the sample size, the appropriate framework ensures that CIs are more likely to be
precise and allows authors to be more confident in their conclusions. Compared to
previous literature, our results underscore existing concerns of p-value misuse and
inconsistent frameworks that have been identified in other biomedical literature.
However, our investigation in the field in the orthopaedic surgery is unique and provides
a novel perspective on these topics. We suspect that the issues we have identified can be
attributed to varied statistical and methodological training of authors and reviewers and
differing journal requirements; improvements in training combined with unified journal
requirements will improve the quality of published research.

4.2 Future Directions
As part of our knowledge translation plan, Chapter 2 has been submitted to the Journal of
Bone and Joint Surgery and the findings of both studies were presented at a number of
events (Fowler Kennedy Sports Medicine Clinic Research Rounds, The Bone and Joint
Trainee Lunch and Learn, and Western Research Forum in London, Ontario). Chapter 2
was also accepted as a podium presentation at the 2020 Canadian Orthopaedic
Association Annual Meeting. Publishing our results and presenting at conferences are
means to engage researchers, which is our target audience, and disseminate our findings.
Additionally, it is known that statistical and methodological training quality during
medical and graduate school can vary by institution1,2. We suggest that academic
programs consider developing consistent and comprehensive statistics, methods, and
critical appraisal training as part of their curriculum. As several orthopaedic journals have
recently published papers highlighting the importance of sound research methodology
and critical appraisal3–6, our results provide evidence of the issues of statistical and
methodological concepts in current orthopaedic literature and similarly support the need
for improvements. Disseminating our findings and amendments to teaching at academic
programs will facilitate critical appraisal of published literature and improve research
quality within the orthopaedic community and beyond.
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We also encourage journal editors to mandate the reporting of important information for
manuscript submissions such as between-group treatment effects with CIs, clinically
important thresholds, and frameworks to provide readers with a meaningful context. To
improve the quality of manuscripts without compromising time and resources, we make
several suggestions that can be implemented. Firstly, journal editors can modify their
author instructions webpages to mandate the inclusion of these important key values. For
example, upon submission, artificial intelligence can be used to screen for these values. If
the authors do not satisfy the requirements, the submission engine would automatically
return the manuscript to authors with a notification to include these values and ask them
to revise before resubmitting their manuscript. For peer-reviewers, the increase in volume
of sub-specializations in orthopaedic surgery and varying degrees of expertise provide
different skillsets to address statistical concerns7. We propose that reviewers be trained to
critically appraise whether these values are included and interpreted appropriately and
notify authors. For example, some journals have implemented reviewer training through
annual reviewer training days to uphold journal standards7. Direct communication with
reviewers can help highlight important concepts and provide individuals with appropriate
appraisal tools. Alternatively, comprehensive online module training may be provided to
a select number of reviewers (similar to a pool of statistical experts), and editors can
ensure that one of these trained reviewers reviews every submitted manuscript. Change
will take time, but a commitment to adhere to high statistical and methodological
standards from authors, editors, and reviewers will improve the quality of evidence in
orthopaedic surgery and, ultimately, help the patients we serve.
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Appendices
Appendix A: Instructions for Reframing for Reviewers
Classification should be based on the characteristics of the interventions as opposed to
the hypothesis or purpose of the trial that authors have provided. Standard of care can be
no treatment, wait and see, a conservative treatment and operative treatment and active
treatment, etc.
A study should be classified as superiority if:
•
•
•

An intervention is being added to the standard of care
An intervention will replace the standard of care
I.e. conservative (usual care) vs operative (since operative carries more risks/most
costly, operative would need to be shown to be superior to conservative)

A study should be classified as non-inferiority if:
•

•
•

An existing intervention (or parts of) is being taken away (i.e. in-person visit
(usual care) being replaced with an eHealth app, inpatient total hip arthroplasty
(THA) (usual care) v outpatient THA)
A treatment that is less costly (but may have more adverse events) is compared to
the standard of care
A treatment is expected to be less effective (but may cost less or have fewer side
effects) compared to standard of care

A study should be classified as equivalence if:
•

Two similar treatments for the same disease are compared (i.e. two common
elbow surgeries for the same elbow problem, plating vs no plating in clavicle
surgery, bone marrow aspirate concentrate (BMAC) vs. platelet rich plasma
(PRP), anterior vs. posterior THA) and the intention is to recommend them as
interchangeable, offering identical outcomes, risk profiles, etc.

A study should be classified as equality if:
•
•

the study is a feasibility study only
the study endpoints are surrogate outcomes or lab-based outcome (not patient
important outcomes)
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